About Biodexa Pharmaceuticals
Biodexa Pharmaceuticals is a Healthcare company based in Cardiff (United Kingdom) founded in 2000. Therapeutics for aggressive rare brain cancers are developed. Biodexa Pharmaceuticals has raised $6.79 million across 1 funding round. Its chief executive, as recorded, is Stephen Stamp. Biodexa Pharmaceuticals offers products and services including eRapa, Tolimidone, and MTX110. Its focus areas include Life Sciences, Oncology, Drugs and Brain Cancer. Its legal entity is Biodexa Pharmaceuticals PLC.
Company details
Biodexa Pharmaceuticals was founded in 2000 and is based in Cardiff, United Kingdom. Focus is placed on the pharmaceutical sector, where therapeutics for brain cancer treatment are developed. The lead candidate, MTX110, consists of a solubilised formulation of the histone deacetylase inhibitor panobinostat. This is targeted at recurrent glioblastoma, medulloblastoma, and paediatric diffuse midline glioma, addressing rare and orphan indications in oncology.
- Headquarters Cardiff, United Kingdom
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website biodexapharma.com
- Social LinkedIn X
- Legal Name Biodexa Pharmaceuticals Plc
- Total Equity Funding$6.79M (USD)
in 1 rounds
- Latest Funding Round$6.79M (USD), Series A
Dec 2023
Products & Services of Biodexa Pharmaceuticals
Biodexa Pharmaceuticals offers a comprehensive portfolio of products and services, including eRapa, Tolimidone, and MTX110.
Oral formulation for treating familial adenomatous polyposis.
Inhibitor for managing type 1 diabetes symptoms.
Treatment for primary and metastatic brain cancers.
Funding Insights of Biodexa Pharmaceuticals
Biodexa Pharmaceuticals has successfully raised a total of $6.79M through 1 strategic funding round. The most recent funding activity was a Series A round of $6.79 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $6.79M
- Total Rounds 1
- Last Round Series A — $6.79M
- First Round $6.79M
(Dec 2023)
All 1 funding rounds of Biodexa Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2023 | $6.79M | Series A | – | – | – |
People of Biodexa Pharmaceuticals
1 people are tracked at Biodexa Pharmaceuticals (1 in leadership).
| Name | Role | Group |
|---|---|---|
Stephen Stamp | CEO | Leadership |
Complete people profiles for Biodexa Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Biodexa Pharmaceuticals
2 dated milestones of Biodexa Pharmaceuticals across 23 years, from founding to its latest funding, stage changes and deals.
- Founded Biodexa Pharmaceuticals is founded.
- Funding First funding round of $6.8M.
Web traffic of Biodexa Pharmaceuticals
The website of Biodexa Pharmaceuticals (biodexapharma.com) receives about 6.5K visits a month.
- Monthly visits6.5K
▲ 47.3% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biodexa Pharmaceuticals
Complete news archive for Biodexa Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biodexa Pharmaceuticals
Biodexa Pharmaceuticals was founded in 2000 and raised its 1st funding round 23 years after it was founded.
Biodexa Pharmaceuticals is headquartered in Cardiff, United Kingdom. It is registered at Cardiff, Wales, United Kingdom.
Stephen Stamp is the CEO of Biodexa Pharmaceuticals, as recorded in our data.
Biodexa Pharmaceuticals is a funded company, having raised a total of $6.79M across 1 funding round to date. The company's 1st funding round was a Series A of $6.79M, raised on Dec 2023.
Biodexa Pharmaceuticals was founded in 2000 and is based in Cardiff, United Kingdom. Focus is placed on the pharmaceutical sector, where therapeutics for brain cancer treatment are developed. The lead candidate, MTX110, consists of a solubilised formulation of the histone deacetylase inhibitor panobinostat. This is targeted at recurrent glioblastoma, medulloblastoma, and paediatric diffuse midline glioma, addressing rare and orphan indications in oncology.
Biodexa Pharmaceuticals offers eRapa, Tolimidone, and MTX110.
Biodexa Pharmaceuticals operates through Biodexa Pharmaceuticals Plc.